Regensburg

• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA … Ended recruitment
  2024-513252-15-00 4 2021-01-28 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
• Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® co … Ended recruitment
  2024-518033-28-00 6 2020-11-27 Prophylaxis of transplant rejection in adult liver allograft recipient
• A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended recruitment
  2022-502052-30-00 5 2020-10-27 Unresectable Esophageal Squamous Cell Carcinoma
• Study with apalutamide in patients with prostate cancer in whom the prostate has been removed who are at high risk of disease recurrence Ended recruitment
  2024-511832-29-00 4 2020-08-05 High risk adenocarcinoma of the prostate after radical prostatectomy (
• A Phase 3 study to compare long-term efficacy and safety of macitentan 75 mg versus 10 mg in Pulmonary Arterial Hypertension. Ended recruitment
  2024-515669-32-00 5 2020-06-30 Pulmonary arterial hypertension
• RACE-trial: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of t … Ended recruitment
  2024-516271-32-00 5 2020-06-03 Adenocarcinoma of the gastroesophageal junction (AEG type I-III)
• A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand s … Ended recruitment
  2024-512682-14-00 4 2020-04-06 Non-resectable hepatocellular carcinoma (HCC)
• ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty … Ended recruitment
  2024-513947-94-00 4 2020-03-30 locally advanced (stage III) and not suitable for curative treatment,
• Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined … Ended recruitment
  2024-511577-29-01 5 2020-03-13 intermediate and high-risk rectal cancer
• Study on the prevention of atopic dermatitis symptoms in children with a high risk of the disease through the regular use of a moisturizing … Ended recruitment
  2024-513289-21-00 5 2020-01-13 Children with a high risk of developing atopic dermatitis
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• RADIANCE Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma A multicenter, randomized, phase II trial of the German Anal C … Ended recruitment
  2024-513914-36-00 4 2019-12-17 locally-advanced Anal Carcinoma, Anal cancer stage II and III
• Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or d … Ended recruitment
  2024-513039-26-00 4 2019-11-25 non-small cell lung cancer stages IIIA (N2) and selected resectable st
• A Study of Atezolizumab (Anti-PD-L1 Antibody) plus Bevacizumab versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellula … Ended recruitment
  2023-504303-86-00 5 2019-11-21 High-risk hepatocellular carcinoma (HCC)
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno … Ended recruitment
  2023-503670-21-00 5 2019-08-28 Patients with newly diagnosed AML and intermediate- or adverse-risk ge
• Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours Ended recruitment
  2023-507582-25-00 5 2019-08-02 Malignant Extracranial Germ Cell Tumours (MGCT)
• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• Study of durvalumab or placebo administered with radiation therapy for patients with early stage non-small cell lung cancer Study of osime … Ended recruitment
  2024-512667-31-00 5 2019-04-23 Main cohort: Patients with unresected Stage I/II, lymph-node negative
• A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr … Ended recruitment
  2023-509834-20-00 4 2019-03-13 untreated FLT3-mutated Acute Myeloid Leukemia
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll … Ended recruitment
  2023-509602-29-00 5 2019-02-11 Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
• This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen … Ended recruitment
  2023-510015-19-00 5 2019-02-11 Patients with histologically or cytologically documented muscle-invasi
• A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio … Ended recruitment
  2024-513464-26-00 5 2018-10-18 Multiple Myeloma

Showing 217–240 of 295 trials